Phase Change Nanodroplet Conjugates for Ultrasound-Triggered Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, such as micelles, face challenges in maintaining stability under physiological conditions, leading to unpredictable and often systemic drug release, which hinders targeted and controlled delivery of therapeutic agents.
Innovation Solution
Phase change nanodroplet conjugates are developed, comprising a gaseous precursor core enclosed by a lipid or polymer shell, with therapeutic or diagnostic nanoparticles attached, allowing for controlled release through ultrasound stimulation, enabling targeted delivery to specific tissues or organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If micelles are used as delivery carriers with drug molecules encapsulated in the core, then targeted delivery is achieved, but the shell layer hinders release of the drug or the micelle breaks down too early under physiological conditions leading to systemic exposure
Solution Approach 1:
The invention uses a gaseous precursor core that undergoes phase transition to liquid upon ultrasound exposure, enabling controlled drug release. The phase change from gas to liquid creates mechanical disruption that releases the drug payload only at the target site, resolving the contradiction between maintaining stability during transport and enabling controlled release at destination.
Solution Approach 2:
The invention transforms the static micelle structure into a dynamic system where the core can change phase from gas to liquid. This dynamic capability allows the delivery system to adapt its state based on external stimulation (ultrasound), enabling it to remain stable during circulation and release drug only when activated at the target site.
2Stability of the object's composition
If the shell layer is maintained stable under physiological conditions, then micelle integrity is preserved, but drug release is hindered
Solution Approach 1:
The gaseous precursor acts as an intermediary between the stable shell structure and the drug payload. The gas core provides internal pressure and structural support that maintains micelle stability, while simultaneously serving as a trigger for controlled release when phase transition occurs upon ultrasound exposure.
Solution Approach 2:
The invention prepares the gaseous precursor in advance within the micelle core, creating a pre-loaded system that is stable during circulation. The preliminary placement of the gas phase material sets up the condition for subsequent controlled release without requiring structural modification of the shell layer.
3Productivity
If the micelle breaks down under physiological conditions to release drug, then drug delivery occurs, but systemic exposure increases and targeting is compromised
Solution Approach 1:
The invention replaces passive chemical degradation or diffusion-based release with active mechanical control through ultrasound-induced phase transition. This substitution allows precise spatial and temporal control of drug release, ensuring delivery function is activated only at the target site rather than through uncontrolled breakdown.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise and controlled release of therapeutic agents, reducing systemic exposure and improving bioavailability by using ultrasound to stimulate vaporization and cavitation, thereby dispersing the drug effectively at the target site without damaging the surrounding tissue.
Implementation Method 1
phase change nanodroplet conjugates... containing a nanodroplet containing a gaseous precursor... applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor
Implementation Method 2
applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor followed by cavitation of the resultant bubble conjugate and release or dispersing of drug or drugs inside the liposomes
Data Source
AI summary
Phase change nanodroplet conjugates and methods of making and using thereof are provided. The phase change nanodroplet conjugates include a nanodroplet having a gaseous precursor on the interior and an outer shell such as a lipid monolayer, a lipid bilayer, or a polymer layer. The phase change nanodroplet conjugates can have one or more nanoparticles attached to the outer layer, e.g. via a linker. The nanoparticles can include therapeutic, prophylactic, or diagnostic nanoparticles. The phase change nanodroplet conjugates can be used for the targeted delivery of a therapeutic, prophylactic, or diagnostic nanoparticle to a target region in a subject in need thereof. The methods can include applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor followed by cavitation of the resultant bubble conjugate and release or dispersing of drug or drugs inside the liposomes. Methods of making phase change nanodroplet conjugates are also provided.